Dandan Wu

Dr. Dandan Wu

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
KYKunlun Yin
Kunlun Yin
JLJordan Lee
Jordan Lee
ZLZhaoli Liu
Zhaoli Liu
HKHyeoncheol Kim
Hyeoncheol Kim
DMDavid R. Martin
David R. Martin
Xiang XueXiang Xue
Xiang Xue

26 October 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LWLu Wang
Lu Wang
YLYan Luo
Yan Luo
LLLiping Luo
Liping Luo
DWDandan Wu
Dandan Wu
XDXiaofeng Ding
Xiaofeng Ding
Meilian LiuMeilian Liu
Meilian Liu
ILC2s are present in adipose tissue and play a critical role in regulating adipose thermogenesis. However, the mechanisms underlying the activation of adipose-resident ILC2s remain poorly defined. Here, we show that IL-33, a potent ILC2 activator, stimulates phosphorylation of AMPK at Thr172 via TAK1 in primary ILC2s, which provides a feedback mechanism to inhibit IL-33–induced NF-κB activation and IL-13 production. Treating ILC2s with adiponectin or an adiponectin receptor agonist (AdipoRon) activated AMPK and decreased IL-33–NF-κB signaling. AdipoRon also suppressed cold-induced thermogenic gene expression and energy expenditure in vivo. In contrast, adiponectin deficiency increased the ILC2 fraction and activation, leading to up-regulated thermogenic gene expression in adipose tissue of cold-exposed mice. ILC2 deficiency or blocking ILC2 function by neutralization of the IL-33 receptor with anti-ST2 diminished the suppressive effect of adiponectin on cold-induced adipose thermogenesis and energy expenditure. Taken together, our study reveals that adiponectin is a negative regulator of ILC2 function in adipose tissue via AMPK-mediated negative regulation of IL-33 signaling.

8 January 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
XZXing Zhang
Xing Zhang
XDXiaofeng Ding
Xiaofeng Ding
CWChunqing Wang
Chunqing Wang
QLQue Le
Que Le
DWDandan Wu
Dandan Wu
Meilian LiuMeilian Liu
Meilian Liu

19 May 2023 in Mucosal Immunology
Verified
Journal Article
Open access
DWDandan Wu
Dandan Wu
XZXing Zhang
Xing Zhang
KZKourtney M. Zimmerly
Kourtney M. Zimmerly
RWRuoning Wang
Ruoning Wang
CWChunqing Wang
Chunqing Wang
Xuexian YangXuexian Yang
Xuexian Yang
The unfolded protein response (UPR) is associated with the risk of asthma, including treatment-refractory severe asthma. Recent studies demonstrated a pathogenic role of activating transcription factor 6a (ATF6a or ATF6), an essential UPR sensor, in airway structural cells. However, its role in T helper (TH) cells has not been well examined. In this study, we found that ATF6 was selectively induced by signal transducer and activator of transcription6 (STAT6) and STAT3 in TH2 and TH17 cells, respectively. ATF6 upregulated UPR genes and promoted the differentiation and cytokine secretion of TH2 and TH17 cells. T cell-specific Atf6-deficiency impaired TH2 and TH17 responses in vitro and in vivo and attenuated mixed granulocytic experimental asthma. ATF6 inhibitor Ceapin A7 suppressed the expression of ATF6 downstream genes and TH cell cytokines by both murine and human memory clusters of differentiation 4 (CD4)+ T cells. At the chronic stage of asthma, administration of Ceapin A7 lessened TH2 and TH17 responses, leading to alleviation of both airway neutrophilia and eosinophilia. Thus, our results demonstrate a critical role of ATF6 in TH2 and TH17 cell-driven mixed granulocytic airway disease, suggesting a novel option to combat steroid-resistant mixed and even T2-low endotypes of asthma by targeting ATF6.

21 May 2021 in Viruses
Verified
Journal Article
Open access
PDF file
DWDandan Wu
Dandan Wu
Xuexian YangXuexian Yang
Xuexian Yang
Patients with coronavirus disease 2019 (COVID-19) predominantly have a respiratory tract infection with various symptoms and high mortality is associated with respiratory failure second to severe disease. The risk factors leading to severe disease remain unclear. Here, we reanalyzed a published single-cell RNA-Seq (scRNA-Seq) dataset and found that bronchoalveolar lavage fluid (BALF) of patients with severe disease compared to those with mild disease contained decreased TH17-type cells, decreased IFNA1-expressing cells with lower expression of toll-like receptor 7 (TLR7) and TLR8, increased IgA-expressing B cells, and increased hyperactive epithelial cells (and/or macrophages) expressing matrix metalloproteinases (MMPs), hyaluronan synthase 2 (HAS2), and plasminogen activator inhibitor-1 (PAI-1), which may together contribute to the pulmonary pathology in severe COVID-19. We propose IFN-I (and TLR7/TLR8) and PAI-1 as potential biomarkers to predict the susceptibility to severe COVID-19.

2 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
CWChunqing Wang
Chunqing Wang
XZXing Zhang
Xing Zhang
LLLiping Luo
Liping Luo
YLYan Luo
Yan Luo
DWDandan Wu
Dandan Wu
Meilian LiuMeilian Liu
Meilian Liu
Cyclooxygenase-2 (COX-2) plays a critical role in regulating innate immunity and metabolism by producing prostaglandins (PGs) and other lipid mediators. However, the implication of adipose COX-2 in obesity remains largely unknown. Using adipocyte-specific COX-2 knockout (KO) mice, we showed that depleting COX-2 in adipocytes promoted white adipose tissue development accompanied with increased size and number of adipocytes and predisposed diet-induced adiposity, obesity, and insulin resistance. The increased size and number of adipocytes by COX-2 KO were reversed by the treatment of prostaglandin E2 (PGE2) but not PGI2 and PGD2 during adipocyte differentiation. PGE2 suppresses PPARγ expression through the PKA pathway at the early phase of adipogenesis, and treatment of PGE2 or PKA activator isoproterenol diminished the increased lipid droplets in size and number in COX-2 KO primary adipocytes. Administration of PGE2 attenuated increased fat mass and fat percentage in COX-2 deficient mice. Taken together, our study demonstrated the suppressing effect of adipocyte COX-2 on adipogenesis and reveals that COX-2 restrains adipose tissue expansion via the PGE2-mediated paracrine mechanism and prevents the development of obesity and related metabolic disorders.